The metabolic syndrome: From an aggravating condition to a pathogenic risk factor for chronic diseases;El síndrome metabólico: De factor agravante a principal factor de riesgo patogénico en diversas enfermedades crónicas

Revista Medica de Chile

Volumn 138, Issue 8, 2010, Pages 1012-1019

  von Bernhardi, Rommy ^a   Zanlungo, Silvana ^a   Arrese, Marco ^a   Arteaga, Antonio ^b   Rigotti, Attilio ^a  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^b PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

Chronic disease; Hyperinsulinism; Metabolic syndrome

Indexed keywords

ARTICLE; CARDIOVASCULAR DISEASE; CHILE; CHRONIC DISEASE; DEMENTIA; HUMAN; METABOLIC SYNDROME X; RISK FACTOR;

CARDIOVASCULAR DISEASES; CHILE; CHRONIC DISEASE; DEMENTIA; HUMANS; METABOLIC SYNDROME X; RISK FACTORS;

EID: 78649255334     PISSN: 00349887     EISSN: 07176163     Source Type: Journal    
DOI: None     Document Type: Article

References (64)

1. Kahn R, Buse J, Ferrannini E, Stern M. The Metabolic Syndrome: Time for a Critical Appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005; 28: 2289-304.
2. Grundy SM. Metabolic syndrome: a multiplex cardiovascular risk factor. J Clin Endocrinol Metab 2007; 92: 399-404.
3. International Diabetes Foundation Backgrounder 1: The IDF consensus worldwide definition of the metabolic syndrome. http://www.idf.org/webdata/docs/ IDF_Meta_def_final.pdf. [Consultado en octubre de 2008].
4. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15: 539-53.
5. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report on The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment on High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97.
6. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al; International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120: 1640-5.
7. Albala C, Vio F, Kain J, Uauy R. Nutrition transition in Chile: determinants and consequences. Public Health Nutrition 2002; 5: 123-8.
8. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome-a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med 2006; 23: 469-80.
9. Valenzuela A, Olivos C, Rigotti A, Margozzini P, Olea R, Maiz A, et al. High level of agreement between the NCEP ATPIII and IDF metabolic syndrome definition in the Chilean general population: Results from the first National Health Survey 2003. Atherosclerosis Suppl 2007; 8: 121-2.
10. Wilson PWF, D'agostino RB, Parise H, Sullivan L, Meigs JB. Metabolic Syndrome as a Precursor of Cardiovascular Disease and Type 2 Diabetes Mellitus. Circulation 2005; 112: 3066-72.
11. Biessels GJ, Kapelle LJ. Increased risk of Alzheimer's disease in type II diabetes: insulin resistance of the brain or insulin-induced amyloid pathology? Biochem Soc Transac 2005; 33: 1041-4.
12. Margozzini P, Rigotti A, Ferreccio C, Quezada N, Garrido M, Valdés G. Hypertension and the cardiometabolic syndrome in Chile: a review of concepts and consequences for the developing world. Ther Adv Cardiovasc Dis 2007; 1: 83-90.
13. Martins IJ, Hone E, Foster JK, Sünram-Lea SI, Gnjec A, Fuller SJ, et al. Apolipoprotein E, cholesterol metabolism, diabetes, and the convergence of risk factors for Alzheimer's disease and cardiovascular disease. Mol Psychiatry 2006; 11: 721-36.
14. Duron E, Hanon O. Vascular risk factors, cognitive decline, and dementia. Vasc Health Risk Manag 2008; 4: 363-81.
15. Milionis HJ, Florentin M, Giannopoulos S. Metabolic syndrome and Alzheimer's disease: a link to a vascular hypothesis? CNS Spectr 2008; 13:606-613.
16. Esposito K, Nappo F, Marfella R, Giugliano G, Giugliano F, Ciotola, et al. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation 2002; 106: 2067-72.
17. Helmersson J, Vessby B, Larsson A, Basu S. Association of Type 2 Diabetes With Cyclooxygenase-Mediated Inflammation and Oxidative Stress in an Elderly Population. Circulation 2004; 109: 1729-34.
18. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414: 813-20.
19. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005; 54: 1615-25.
20. Nishikawa T, Edelstein D, Du Xl, Yamagishi S, Matsumura T, Kaneda Y, et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000; 404: 787-90
21. Nigro J, Osman N, Dart AM, Little PJ. Insulin resistance and atherosclerosis. Endocr Rev 2006; 27: 242-59.
22. Gutterman DD, Miura H, Liu Y. Redox modulation of vascular tone: focus of potassium channel mechanisms of dilation. Arterioscler Thromb Vasc Biol 2005; 25: 671-8.
23. Van Oijen M, De Jong FJ, Witteman JCM, Hofman A, Koudstaal PJ, Breteler MMB. Atherosclerosis and Risk for Dementia. Ann Neurol 2007; 61: 403-10.
24. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005; 365: 1415-28.
25. Raal FJ. Pathogenesis and management of the dyslipidemia of the metabolic syndrome. Metab Syndr Relat Disord 2009; 7: 83-8.
26. Blomhoff JP. Lipoproteins, lipases, and the metabolic cardiovascular syndrome. J Cardiovasc Pharmacol 1992; 20: S22-5.
27. Lamarche B, Paradis ME. Endothelial lipase and the metabolic syndrome. Curr Opin Lipidol 2007; 18: 298-303.
28. Rashid S, Uffelman KD, Lewis GF. The mechanism of HDL lowering in hypertriglyceridemic, insulin-resistant states. J Diabetes Complications 2002;16: 24-8.
29. Deeb SS, Zambon A, Carr MC, Ayyobi AF, Brunzell JD. Hepatic lipase and dyslipidemia: interactions among genetic variants, obesity, gender, and diet. J Lipid Res 2003; 44: 1279-86.
30. Rizzo M, Berneis K. Small, dense low-density-lipoproteins and the metabolic syndrome. Diabetes Metab Res Rev 2007; 23: 14-20.
31. Kotronen A, Yki-Jarvinen H. Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol 2008; 28: 27-38.
32. Kim CH, Younossi ZM. Nonalcoholic fatty liver disease: a manifestation of the metabolic syndrome. Cleve Clin J Med 2008; 75: 721-8.
33. Adams LA, Angulo P. Recent concepts in non-alcoholic fatty liver disease. Diabet Med 2005; 22: 1129-33.
34. Brunt EM. Pathology of fatty liver disease. Mod Pathol 2007; 20 Suppl 1: S40-8.
35. Riquelme A, Arrese M, Soza A, Morales A, Baudrand R, Pérez-Ayuso RM, et al. Non-alcoholic fatty liver disease and its association with obesity, insulin resistance and increased serum levels of C-reactive protein in Hispanics. Liver Int 2008; 29: 82-8.
36. Boza C, Riquelme A, Ibáñez L, Duarte I, Norero E, Viviani P, et al. Predictors of nonalcoholic steatohepatitis (NASH) in obese patients undergoing gastric bypass. Obes Surg 2005; 15: 1148-53.
37. Cusi K. Nonalcoholic fatty liver disease in type 2 diabetes mellitus. Curr Opin Endocrinol Diabetes Obes 2009; 16: 141-9.
38. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40: 1387-95.
39. Edens MA, Kuipers F, Stolk RP. Non-alcoholic fatty liver disease is associated with cardiovascular disease risk markers. Obes Rev 2009; 10: 412-9.
40. Haffner SM, Diehl AK, Mitchell BD, Stern MP, Hazuda HP. Increased prevalence of clinical gallbladder disease in subjects with non insulin dependent diabetes mellitus. Am J Epidemiol 1990; 132: 327-35.
41. Attili AF, Capocaccia R, Carulli N, Festi D, Roda E, Barbara L, et al. Multicenter Italian Study on Epidemiology of Cholelithiasis. Factors associated with gallstone disease in the MICOL experience. Hepatology 1997; 26: 809-18.
42. Reaven GM. Banting lecture 1988: role of insulin resistance in human disease. Diabetes 1988; 37: 1595-607.
43. Nervi F, Miquel JF, Álvarez M, Ferreccio C, García- Zattera MJ, González R, et al. Gallbladder disease is associated with insulin resistance in a high risk Hispanic population. J Hepatol 2006; 45: 299-305.
44. Wang DQ, Cohen DE, Carey MC. Biliary lipids and gallstone formation. J Lipid Res 2009; 50: S406-11.
45. Tsai CJ, Leitzmann MF, Willett WC, Giovannucci EL. Macronutrients and insulin resistance in cholesterol gallstone disease. Am J Gastroenterol 2008; 103: 2932-9.
46. Biddinger SB, Haas JT, Yu BB, Bezy O, Jing E, Zhang W, et al. Hepatic insulin resistance directly promotes formation of cholesterol gallstones. Nat Med 2008; 14: 778-82.
47. Regitz-Zagrosek V, Lehmkuhl E, Weickert MO. Gender differences in the metabolic syndrome and their role for cardiovascular disease. Clin Res Cardiol 2006; 95: 136-47.
48. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, et al. Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 2004; 44: 720-32.
49. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and Management of the Metabolic Syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112: 2735-52.
50. Jiamsripong P, Mookadam M, Honda T, Khandheria BK, Mookadam F. The metabolic syndrome and cardiovascular disease: Part I. Prev Cardiol 2008; 11: 155-61.
51. Boyle PJ. Metabolic syndrome and macrovascular disease: mechanisms and mediators. Am J Med 2007; 120: S12-17.
52. Selkoe DJ. Alzheimer's disease: genes, proteins and therapy. Physiol Rev 2001; 81: 741-66.
53. Casserly I, Topol E. Convergence of atherosclerosis and Alzheimer's disease: Inflammation, cholesterol, and misfolded proteins. Lancet 2004; 363: 1139-46.
54. Román GC. Vascular dementia prevention: a risk factor analysis. Cerebrovasc Dis 2005; 20: 91-100.
55. Razay G, Vreugdenhil A, Wilcock G. The metabolic syndrome and Alzheimer disease. Arch Neurol 2007; 64: 93-6.
56. Vanhanen M, Koivisto K, Moilanen L, Helkala, El, Hänninen, T, Soininen, H, et al. Association of metabolic syndrome with Alzheimer disease: a population-based study. Neurology 2006; 67: 843-7.
57. Craft S. The role of metabolic disorders in Alzheimer disease and vascular dementia. Arch Neurol 2009; 66: 300-5.
58. Erol A. An integrated and unifying hypothesis for the metabolic basis of sporadic Alzheimer's disease. J Alzheimer Dis 2008; 13: 241-53.
59. Wolozin B, Brown J, Theisler C, Silberman S. The cellular biochemistry of cholesterol and statins: insights into the pathophysiology and therapy of Alzheimer's disease. CNS Drug Rev 2004; 10: 127-46.
60. Whitmer RA, Sidney S, Selby J, Jonston SC, Yafte K. Midlife cardiovascular risk factors and risk of dementia in late life. Neurology 2005; 64: 277-81.
61. Early J. Comprehensive management of cardiometabolic risk factors. Clin Cornerstone 2007; 8: 69-80.
62. Pasinetti GM, Eberstein JA. Metabolic syndrome and the role of dietary lifestyles in Alzheimer's disease. J Neurochem 2008; 106: 1503-14.
63. Ziemke F, Mantzoros CS. Adiponectin in insulin resistance: lessons from translational research. Am J Clin Nutr 2010; 91: 258S-61S.
64. Khan T, Hamilton MP, Mundy DI, Chua SC, Scherer PE. Impact of Simvastatin on Adipose Tissue: Pleiotropic Effects in Vivo. Endocrinology 2009; 150: 5262-72.